

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|----------------------|------------------------|-----------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | Application Number | 10/780,325 | |
| | Filing Date | Feb 17, 2004 | |
| | First Named Inventor | Quay, Steven C. | |
| | Art Unit | 1614 | |
| | Examiner Name | | |
| Total Number of Pages in This Submission | 10 | Attorney Docket Number | 02-04CIP3 |


| ENCLOSURES (Check all that apply) | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement Form 1449, 7 pages <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance communication to (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input checked="" type="checkbox"/> Information Disclosure Statement for 37 CFR <input type="checkbox"/> Other Enclosure(s) (please identify below): |
| Remarks | | |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | |
|--|-------------------------------------|----------|--------|
| Firm Name | Nastech Pharmaceutical Company Inc. | | |
| Signature | | | |
| Printed name | Paul G. Lunn | | |
| Date | January 13, 2005 | Reg. No. | 32,743 |

| CERTIFICATE OF TRANSMISSION/MAILING | | | |
|--|--------------------|------|------------------|
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as priority mail in an priority mail box, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. | | | |
| Signature | | | |
| Typed or printed name | Jeffrey L. Granger | Date | January 13, 2005 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Quay *et al.*

U.S. Application Patent Serial No.:
10/780,325

Filed: 2/17/2004

Title: COMPOSITIONS AND METHODS
FOR ENHANCED MUCOSAL
DELIVERY OF Y2 RECEPTOR-
BINDING PEPTIDES AND
METHODS FOR TREATING AND
PREVENTING OBESITY

Assignee: Natestch Pharmaceutical Company
Inc. by assignment recorded on 06/03/2004,
Reel/Frame 014680/0942

Group Art Unit: 1614

Attorney Docket No.: 02-04CIP3

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

- ☒ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of international application; or **before mailing date of first office action on the merits**; whichever occurs last)
- ☐ under 37 CFR 1.97(c) together with either a:
☐ Statement under 37 CFR 1.97(e), or
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with a:
☐ Statement under 37 CFR 1.97(e), and
☐ a \$180.00 fee set forth in 37 CFR 1.17(p).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,




Paul G. Lunn
Attorney/Agent for Applicant(s)
Reg. No. 32743


Date: January 13, 2005
Telephone No.: (425) 908-3643
Facsimile No.: (425) 908-3655

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for priority mail in a box, priority mail delivery confirmation number 0103 8555 7494 1289 2450 addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Date of Deposit: January 13, 2005

Typed Name: Jeffrey L. Granger

Signature: 



PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-----------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10780,325 | |
| | | | Filing Date | 02/17/2004 | |
| | | | First Named Inventor | Quay, Steven C. | |
| | | | Art Unit | 1654 | |
| Sheet | 1 | of | 7 | Examiner Name | |
| | | | | Attorney Docket Number | 02-04CIP3 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|---------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Issued Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | | US- 5,308,620 | Issued 05-03-1994 | Hemosphere, Inc. | |
| | | US- 5,574,010 | 11-12-1996 | The Regents of The University of California | |
| | | US- 5,604,203 | Issued 02-18-1997 | University of Cincinnati | |
| | | US- 5,616,311 | Issued 04-01-1997 | Hemosphere, Inc. | |
| | | US- 5,696,093 | Issued 12-09-1997 | CRC for Biopharmaceutical Research Pty Limited | |
| | | US- 5,716,643 | Issued 02-10-1998 | Hemosphere, Inc. | |
| | | US- 5,725,804 | Issued 03-10-1998 | Hemosphere, Inc. | |
| | | US- 5,759,656 | Issued 06-02-1998 | Novartis Corporation | |
| | | US- 5,945,033 | Issued 08-31-1999 | Hemosphere, Inc. | |
| | | US- 5,912,227 | 06-15-1999 | North Carolina State University | |
| | | US- 5,968,748 | Issued 10-19-1999 | Isis Pharmaceuticals, Inc. The Penn State Research Foundation | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | | EP 1 288 223 A1 | 05.03.2003 | Biomeasure Incorporated. | | |
| | | EP 1 288 224 A1 | 05.03.2003 | Biomeasure Incorporated | | |
| | | EP 0 678 018 B1 | 09.04.2003 | Kinerton Limited | | |
| | | EP 1 051 194 B1 | 14.05.2003 | Kinerton Limited | | |
| | | EP 1 466 610 A1 | 13.10.2004 | Daiichi Santory Pharma Co., Ltd. | | |
| Examiner Signature | | | Date Considered | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-----------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/780,325 | |
| | | | Filing Date | 02/17/2004 | |
| | | | First Named Inventor | Quay, Steven C. | |
| | | | Art Unit | 1614 | |
| Examiner Name | | | | | |
| Sheet | 2 | of | 7 | Attorney Docket Number | 02-04CIP3 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|---------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Issued Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | | US- 5,977,175 | Issued 11-02-1999 | Cedars-Sinai Medical Center | |
| | | US- 5,980,945 | Issued 11-09-1999 | Societe de Conseils de Recherches et d'Applications Scientifique Recherches S.A. d'Applications Scientifique S.A. | |
| | | US- 6,013,285 | Issued 01-11-2000 | Hemosphere, Inc. | |
| | | US- 6,013,633 | 1-11-2000 | University of Cincinnati | |
| | | US- 6,017,879 | 01-25-2000 | B.M.R.A. Corporation B.V. | |
| | | US- 6,046,167 | Issued 04-04-2000 | University of Cincinnati | |
| | | US- 6,191,102 | Issued 02-01-2001 | Eli Lilly and Company | |
| | | US- 6,264,988 | Issued 07-24-2001 | Hemosphere, Inc. | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|---|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | | |
| | | PCT WO 94/22467 A1 (International Application Number PCT/US94/03380) | | 10-13-1994 | University of Cincinnati | | |
| | | PCT WO 98/20885 A1 (International Application Number PCT/US96/18374) | | 05-22-1998 | University of Cincinnati | | |
| | | PCT WO 99/02135 A1 (International Application Number PCT/IT98/00192) | | 01.21.1999. | Sierovacciongeno Italiano I.S.I. S.P.A. | | |
| | | PCT/ WO 09915516 A1 (JP) | | 04-01-1999 | Banyu Pharm Co LTD | | |
| Examiner Signature | | | | | Date Considered | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-----------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/780,325 | |
| | | | Filing Date | 02/17/2004 | |
| | | | First Named Inventor | Quay, Steven C. | |
| | | | Art Unit | 1614 | |
| Examiner Name | | | | | |
| Sheet | 3 | of | 7 | Attorney Docket Number | 02-04CIP3 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|---------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Issued Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | | US- 6,391,343 | Issued 05-21-2002 | Hemosphere, Inc. | |
| | | US- 6,235,718 | Issued 05-22-2001 | The University of Cincinnati | |
| | | US- 6,558,708 | Issued 05-06-2003 | Cedars-Sinai Medical Center | |
| | | US- 6,583,111 | Issued 06-24-2003 | Eli Lilly and Company | |
| | | US- 6,737,408 | Issued 05-18-2004 | University of Cincinnati | |
| | | US 2004/0228846 A1 | Publication 11-18-2004 | Ropes & Gray LLP | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | | PCT WO 00/47219 A2 (International Application Number PCT/US00/03391) | 08-17-2000 | Ontogeny, Inc. | | |
| | | PCT WO 02/47712 A2 (International Application Number PCT/US01/48336) | 06-20-2002 | Amylin Pharmaceuticals, Inc. | | |
| | | PCT WO 03/026591 A2 (International Application Number PCT/US02/31944) | 04-03-2003 | Imperial College Innovations Ltd, Oregon Health and Science University | | |
| | | PCT WO 03/057235 A2 (International Application Number PCT/GB03/00062) | 07-17-2003 | Imperial College Innovations Ltd, Oregon Health and Science University | | |
| | | PCT WO 03/105763 A2 (International Application Number PCT/US03/18657) | 12.24.2003 | Amylin Pharmaceuticals, Inc. | | |
| Examiner Signature | | | | Date Considered | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 7

Complete If Known

| | |
|------------------------|-----------------|
| Application Number | 10/780,325 |
| Filing Date | 02/17/2004 |
| First Named Inventor | Quay, Steven C. |
| Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | 02-04CIP3 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|----------|--|----------------|
| | | MEI-HUEI CHEN; BALASUBRAMANIAN; MURPHY; TABATA; FISCHER; CHEN; JOFFE, Sensitive Radioimmunoassay for Measurement of Circulating Peptide YY, Gastroenterology, 1984, Pages 1332-1338, Volume 87, Publisher: American Gastroenterological Association, Published in: Cincinnati, Ohio | |
| | | MORLEY, JOHN E.; LEVINE, ALLEN S.; GRACE, MARTHA; KNEIP, JULIE, "Peptide YY (PYY), a potent orexigenic agent," Brain Research, 1985, Vol. 341, Pages 200-203. Elsevier Science Publishers. | |
| | | JOHN E. MORLEY AND JAMES F. FLOOD, An Investigation of Tolerance to the actions of Leptogenic and Anorexigenic Drugs in Mice, Life Sciences, 9/10/1987, Page(s) 22157-2165, Volume 41, Publisher: Pergamon Journals, Published in: Sepulveda, CA, US | |
| | | KAZUHIKO TATEMOTO; NAKANO; MAKK; ANGWIN; MANN; SCHILLING; GO, Isolation and Primary Structure of Human Peptide YY, Biochemical and Biophysical Research Communications, 10/31/1988, Pages 713-717, Volume 157(2), Publisher: Academic Press, Inc., Published in: Los Angeles, California, US | |
| | | BALASUBRAMANIAM, A.; SERVIN, A. L.; RIGEL, D. F.; ROUYER-FESSARD, C. R.; LABURTHE, M., Syntheses and receptor affinities of partial sequences of peptide YY (PYY) Peptide Research., date- 1988, volume 1, No. 1, pages 32-35 | |
| | | JOHN E. MORLEY, An approach to the development of drugs for appetite disorders, Neuropsychobiology, Date 1989, Volume 21, issue 1, pages 22-30, Karger AG, Basel | |
| | | EBERLEIN, G. A.; EYSSELEIN, V. E.; SCHAEFFER, M.; LAYER, P.; GRANDT, D.; GOEBELL, H.; NIEBEL, W.; DAVIS, M.; LEE, T. D.; SHIVELY, J. E.; REEVE, J. R., JR.; A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36) Peptides, DATE- 1989, Vol 10, No. 4, pages 797-803, Pergamon Press, US | |
| | | EYSSELEIN, V. E.; EBERLEIN, G. A.; GRANDT, D.; SCHAEFFER, M.; ZEHRES, B.; BEHN, U.; SCHAEFER, D.; GOEBELL, H.; DAVIS, M.; LEE, T. D.; SHIVELY, J. E.; MEYER, H. E.; REEVE, J. R., JR., Structural characterization of canine PYY, Peptides, 06/15/1989, Vol. 11 Pages 111-116, Pergamon Press, US | |
| | | HIROYUKI MINAKATA, TAKASHI IWASHITA, Synthesis of analogues of peptide YY with modified N-terminal regions: relationships of amphiphilic secondary structures and activity in rat vas deferens, Journal: Biopolymers, Vol 29, 1/29/1990, pages 61-67, John Wiley & Sons, Inc. | |
| | | RAMO, O. J.; BALASUBRAMANIAM, A.; SHERIFF, S.; ROGERS, D. H.; MCCULLOUGH, P. J.; BELL, R. H., JR., Neuropeptide Y and peptide YY stimulate the growth of exocrine pancreatic carcinoma cells, Neuropeptides, 1990, vol 15, pages 101-106, Longman Group UK | |
| | | S.F. LEIBOWITZ, J.T. ALEXANDER, Analysis of Neuropeptide Y-Induced Feeding: Dissociation of Y1 and Y2 Receptor Effects on Natural Meal Patterns, Peptides, 7/25/1991, Pages 1251-1260, Volume 12, Publisher: Pergamon Press, Published in: New York NY, US | |
| | | MARC LABURTHE, Peptide YY et neuropeptide Y dans L'intestin: disponibilite, effets biologiques et recepteurs epitheliaux, [translated title: Peptide YY and neuropeptide Y in the intestine: availability, biologic effects and epithelial receptors] Arch Int. Physiol Biochim Biophys, Reunion Complementaire de Physiologie, Association des Physiologistes, Toulouse 26-27, 04/1991, France. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | |
|--|---|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Application Number | 10/780,325 |
| | | | Filing Date | 02/17/2004 |
| | | | First Named Inventor | Quay, Steven C. |
| | | | Art Unit | 1614 |
| | | | Examiner Name | |
| (Use as many sheets as necessary) | | | Attorney Docket Number | 02-04CIP3 |
| Sheet | 5 | of | 7 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | INUI AKIO, MINORU OKITA, MASAHARU NAKAJIMA, TORU INOUE, NORIAKI SAKATANI, MANABU OYA, HIDEKI MORIOKA, YASUHIKO OKIMURA, KAZUO CHIHARA, AND SHIGEAKI BABA, Neuropeptide regulation of feeding in dogs, Neuropeptides and Food Intake, 1991, Pages R5888-R594, 0363-6119, The American Physiological Society | |
| | | GRANDT, D.; TEYSSEN, S.; SCHIMICZEK, M.; REEVE, J. R., JR.; FETH, F.; RASCHER, W.; HIRCHE, H.; SINGER, M. V.; LAYER, P.; GOEBELL, H.; HO, F. J.; EYSSELEIN, V. E.: Novel generation of hormone receptor specificity by amino terminal processing of peptide YY, Biochemical and Biophysical Research Communications, 08/14/1992, volume 186, no. 3, pages 1299-1306, Academic Press, Inc. | |
| | | S. OKADA, OHSHIMA, MORI, K. TATEMOTO, Peripherally not Centrally Administered Peptide YY(PYY) Decreases High Fat Diet Intake, 6/9/1993, Volume 520, Publisher: Endocrinology, Published in: Gunmo, Japan | |
| | | GRANDT, D.; SCHIMICZEK, M.; STRUK, K.; SHIVELY, J.; EYSSELEIN, V. E.; GOEBELL, H.; REEVE, J. R., JR - Characterization of two forms of peptide YY, PYY(1-36) and PYY(3-36), in the rabbit, Peptides, 07/29/1994, Volume 15, no 5, pages 815-820, Pergamon, Elsevier Science Ltd, US | |
| | | DUMONT, YVAN.; CADIEUX, ALAIN.; PHENG, L. H.; FOURNIER, A.; ST PIERRE, S.; QUIRION, R., Peptide YY derivatives as selective neuropeptide Y/peptide YY ¹ and Y ² agonists devoided of activity for the Y ₃ receptor sub-type, Brain Research.Molecular.Brain Research, - 06/28/1994, Vol 26, no 1-2, pages 320-324, Elsevier Science B.V. | |
| | | WLODARCZYK-BISAGA K.; BISAGA A., Biologiczne aspekty zaburzeń odżywiania się – wybrane zagadnienia [Selected issues of biological aspects of eating disorders], Psychiatria Polska, 1994 Sep-Oct; vol. 28, no. 5: pages 579-591. Poland. | |
| | | MARGARET DOS SANTOS MEDEIROS, M. D.; ANTHONY J. TURNER, Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11, Endocrinology 1994, Vo 134, No. 5, pages 2088-2094, The Endocrine Society, US | |
| | | GRANDT, D.; SCHIMICZEK, M.; BEGLINGER, C.; LAYER, P.; GOEBELL, H.; EYSSELEIN, V. E.; REEVE, J. R., JR, Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36, Regulatory Peptides, 5-5-1994, Vol 51, No. 2, Pages 151-159, Elsevier Sciences B.V. | |
| | | KAZUHIKO TATEMONO, New Developments in Research on digestive tract hormones, Progress in Medicine, Vol 15, No. 9, date 09/1995, pages 1793-1804, 46 th Pepsin Research Meeting (translated from Japanese) JP | |
| | | NORIO TANI, Digestive Tract Hormones, Digestive Tract, 1996, Article Serial No.: 0012 (translated from Japanese) JP | |
| | | GUE, M.; JUNIEN, J. L.; REEVE, J. R., JR.; RIVIER, J.; GRANDT, D.; TACHE, Y, Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats, British Journal of Pharmacology, 05/1996, pages 118(2), 237-242, Stockton Press | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|--------------------------|-----------------|------------------------|-----------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/780,325 | | |
| | | Filing Date | 02/17/2004 | | |
| | | First Named Inventor | Quay, Steven C. | | |
| | | Art Unit | 1614 | | |
| Sheet | 6 | of | 7 | Examiner Name | |
| | | | | Attorney Docket Number | 02-04CIP3 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|--|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | VON E. NIEBERGALL-ROTH, S. TEYSSEN K. RIPPEL UND M.V. SINGER, Die wirkungen von peptide yy auf funktionen des gastrointestinaltraktes, Dtsch. Tierarztl. Wschr 104, pages 85-124, Heft 3, Marz 1997, National Library of Medicine (article in German) | |
| | | KAZUHIKO TATEMOTO, Chemical and clinical Applications of Digestive Tract hormones, Digestive Tract hormones, 1994, pages 38-45, Vol. 2, no. 4, G. I. Research (translated Japanese article) JP | |
| | | CHEN, C. H.; STEPHENS, R. L., JR.; ROGERS, R. C., PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC, Neurogastroenterol.Motil. 1997, pages 109-116, volume 9, Blackwell Science Ltd., US | |
| | | XIAO, Q.; HAN, X.; ARANY, E.; HILL, D.; CHALLIS, J. R.; MCDONALD, T. J., Human placenta and fetal membranes contain peptide YY1-36 and peptide YY3-36, Journal of Endocrinology, 1998, pages 485-492, Vol 156, Journal of Endocrinology Ltd, UK | |
| | | NARUTO YAMAWAKI, YASUAKI OKAMOTO, Is there a biological case for eating disorders? From the perspective of neurochemistry, Brian Science, 1998, pages 29-36, Article Serial Number 0003, volume 20, Special Edition (Eating Disorders and Obesity) Think also presented at conference 04/24/1998 at Showa University, Yokohama, Japan (translated Japanese article) JP | |
| | | NOBORU YANAIHARA, VIP, PYY and Others, All About Hormone Illustrated No. 381, 1998, page 382-387, Article Serial Number 0033, volume 46, VI. Gastrointestinal Hormones, (translated Japanese article) JP | |
| | | KAZUHIKO TATEMOTO, Development of Neuropeptide Y Receptor Antagonists, Research on Biologically Active Substances, Research Papers of the Suzuken Memorial Foundation, Vol. 14, page 243-244 (translated Japanese article) JP | |
| | | DAVID A. KEIRE, MITSUO KOBAYASHI, TRAVIS E. SOLOMON, JOSEPH R. REEVE, JR., Solution structure of monomeric peptide YY supports the functional significance of the PP-Fold, Biochemistry 2000, pages 9935-9942, 11/8/1999, American Chemical Society, published on web 07/21/2000, US | |
| | | PHILIPPE NAVEILHAN, HESSAMEH HASSANI, JOSEP M. CANALS, A. JONAS EKSTRAND, ASA LAREFALK, VIJAY CHHAJLANI, ERNEST ARENAS, KARIN GEDDA, LENNART SVENSSON, PETER THOREN, AND PATRIK ERNFORS, Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor, Nature America Inc. 10/1999, pages 1188-1193, volume 5, number 10, Nature Medicine | |
| | | AKIHIRO ASAKAWA, AKIO INUI, NAOHIKO UENO, MINEKO FUJIMIYA, MASAYUKI A. FUJINO, MASATO KASUGA, Mouse pancreatic polypeptide modulated food intake, while not influencing anxiety in mice, Peptides, 1999, pages 1445-1448, Volume 20, Elsevier Science Inc. | |
| | | KEIRE, D. A.; MANNON, P.; KOBAYASHI, M.; WALSH, J. H.; SOLOMON, T. E.; REEVE, J. R., JR., Primary structures of PYY, [Pro ³⁶]PYY, and PYY-(3-36) confer different conformations and receptor selectivity, Am.J.Physiol Gastrointest.Liver Physiol, 2/1/2000, page G126-G131, Volume 279 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|--------------------------|------------------------|-----------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/780,325 | |
| | | | Filing Date | 02/17/2004 | |
| | | | First Named Inventor | Quay, Steven C. | |
| | | | Art Unit | 1614 | |
| Sheet | 7 | of | 7 | Examiner Name | |
| | | | | Attorney Docket Number | 02-04CIP3 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | RACHEL L. BATTERHAM, MICHAEL A. COWLEY, CAROLINE S. SMALL, HERBERT HERZOG, MARK A. COHEN, CATHERINE L. DAKIN, ALISON M. WREN, AUDREY E. BRYNES, MALCOM J. LOW, MOHAMMAD A. GHATEI, ROGER D. CONE, STEPHEN R. BLOOM. "Gut hormone PYY3-36 physiologically inhibits food intake," Nature, 2002, Vol. 418, Pages 650-654, Nature Publishing Group. | |
| | | HERBERT HERZOG, Hypothalamic Y2 Receptors: Central Coordination of Energy Homeostasis and Bone Mass Regulation, Drug News Perspect. 10/2002, pages 506-510, Volume 15 (8), Prous Science | |
| | | BATTERHAM, RACHEL. L.; COHEN, MARK. A.; ELLIS, SANDRA. M.; LE ROUX, CAREL. W.; WITHERS, DOMINIC. J.; FROST, GARY. S.; GHATEI, M. A.; BLOOM, S. R., Inhibition of food intake in obese subjects by peptide YY3-36, The New England Journal of Medicine, DATE- 9-4-2003, pages 941-948, vol 349, | |
| | | RACHEL L. BATTERHAM, STEPHEN R. BLOOM, The gut hormone peptide YY regulates appetite , N.Y.Academy.of Sciences, 2003, pages 162-168, volume 994, | |
| | | R. L. BATTERHAM, C.W. LE ROUX, M.A. CHOEN, A.J. PARK, S.M. ELLIS, M. PATTERSON, G.S. FROST, M.A.GHATEI AND S.R. BLOOM, Pancreatic polypeptide reduces appetite and food intake in humans, The Journal of Clinical Endocrinology and Metabolism, 2003, pages 3989-3992, vol 88(8), the Endocrine Society, US | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.